MedTrace Logo

LH-001 vs Placebo in Healthy Participants

NCT06546449 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of LH-001 when administered as an oral, single or multiple dose(s) at ascending dose levels in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

LH-001

LH-001 will be administered oral

DRUG

Placebo

Placebo will be administered oral

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Chien-Liang Lin

    lead OTHER

Principal Investigators

  • Chien-Liang Glenn Lin, PhD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06546449 on ClinicalTrials.gov